Healthy AgingNCT07760506
The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health
A study testing Quercetin (dietary supplement), Coenzyme Q10 and Rice Flour in people with Healthy Aging and Inflammaging, run by Applied Science & Performance Institute at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 50 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Aging, Inflammaging, Metabolic Health
- What is being tested?
- Quercetin (dietary supplement), Coenzyme Q10 and Rice Flour
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 18 Sep 2026to Aug 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males and females aged 50 to 75 years
- Participants who meet the requirements of a sedentary lifestyle. Meaning, subjects who do not meet the World Health Organization's (WHO) minimum activity guidelines, of at least 150 minutes of moderate-intensity activity, or, 75 minutes of vigorous-intensity activity a week, plus muscle-strengthening activities at least 2 days per week. Of importance, incidental physical activity (eg, walking to work, household activities) would not meet the standard of being physically active according to WHO guidelines (McKay et al., 2021).
- BMI of > or equal to 25.00kg/m²
- Individuals with > or equal to 5 score relative to high risk for prediabetes as defined by the CDC (https://www.cdc.gov/prediabetes/takethetest)
- Free of all other chronic diseases.
- Not currently using glucose-lowering agents or insulin.
Show all 12Show fewer
- Able to read and write in English
- Willing to maintain a habitual diet, supplement routine, and avoid other lifestyle changes during the study period.
- During the study, participants agree not to take any other supplement that can impact glucose or insulin regulation.
- During the study, participants agree not to take any other supplement that can impact cardiovascular health, inflammatory status, or anti-aging supplements
- Willing to have blood drawn
- Must have access to a reliable internet connection and a computer to complete remote assessments
Who cannot join
- Unwilling to have blood drawn
- Unwilling to swallow pills
- Pregnancy or has breast fed within 3 months prior to enrollment
- Current use of prescription medication or drug that impacts Glucose or Insulin metabolism (including direct insulin treatment) within the past 6-months
- Current use of Quercetine or CoQ10 supplements within the past 4-weeks
- History or current alcohol or drug abuse
Show all 18Show fewer
- Known diagnosis of any chronic cardiovascular, metabolic, endocrine, or renal disease outside of prediabetes as listed above.
- Has significant concurrent illnesses (controlled or uncontrolled), such as lupus, hepatitis B/C, HIV, serious mental health illness such as dementia or schizophrenia; psychiatric hospitalization in the past two years, or other conditions, which in the opinion of the investigator, such condition might be aggravated as a result of treatment
- Developmental disability or cognitive impairment that would preclude adequate comprehension of the informed consent form and/or ability to follow study subject requirements and/or record the necessary study measurements.
- History of cardiovascular disease (i.e., myocardial infarction, hypertension, hypercholesterolemia, peripheral vascular disease, other)
- History of neurological disorders (Parkinson's, Amyotrophic lateral sclerosis, epilepsy, spinal cord injury resulting in inability to use upper extremities, other.)
- History of gastrointestinal disorders that could lead to uncertain absorption of the study supplements (i.e., inflammatory bowel disease, ulcerative colitis, -Crohn's disease, colostomy, or eating disorder)
- History of kidney or liver disease
- History of metabolic disorders (diabetes, metabolic syndrome, other)
- History of current malignancy/cancer
- Receiving chemotherapy agents or radiation treatments
- Diagnosis of a terminal illness
- The investigator feels that, for any reason, the subject is not eligible to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
The Applied Science and Performance Institute
Tampa, Florida, 33634
Gabe Wilson, PhD, 8136738888, gwilson@theaspi.com
Eric Sikorski, PhD, 8136738888, eskiorski@theaspi.com
About this study
Official title: The Effects of Quercefit® and Ubiqsome™ in Mitigating Inflammation and Promoting Metabolic Health - A Randomized, Double-Blind, Placebo-Controlled Study
The goal of this clinical trial is to learn if Quercefit® or Ubiqsome™ can improve markers of healthy aging, blood sugar control, and heart health in older adults. It will also learn about the safety of these supplements.
The main questions it aims to answer are:
Read more
- Do Quercefit® or Ubiqsome™ improve blood sugar, cholesterol, and markers of aging compared to a placebo?
- What side effects, if any, do participants have while taking these supplements?
Researchers will compare Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), and a placebo (a look-alike capsule with no active ingredient).
Participants will:
- Take their assigned capsules (Quercefit®, Ubiqsome™, or placebo) twice daily for 12 weeks
- Go to a preferred clinic at the start and end of the study for a fasting blood draw Complete at-home tests:
- Grip strength testing (using a device mailed to them)
- Online surveys about fatigue and quality of life
- Report any side effects and keep track of supplement use
Read the detailed description
This study will be a randomized, double-blind, placebo-controlled clinical study conducted over a 12-week intervention investigating the effects of Quercefit® (500 mg daily, 250 mg twice daily), Ubiqsome™ (300 mg daily, 150 mg twice daily), or a placebo (twice daily). Participants will be recruited nationally in a decentralized format and will complete testing procedures remotely, with blood draws conducted through partner labs and electronic survey assessments. Key biomarkers of inflammaging, phenotypic aging, biological age, glucose regulation, insulin sensitivity, insulin resistance, lipid profile, and cardiovascular health will be examined through repeated assessments as described below.
This study will enroll 60 sedentary men and women, selected based on the inclusion and exclusion criteria defined in the protocol. Only individuals who meet all inclusion criteria and none of the exclusion criteria will be considered eligible. Recruitment will occur through an online participant database, through which applicants will be sent initial subject material. To begin enrollment, participants will complete screening to verify they are clinically overweight to obese (BMI ≥ 25.00 kg/m²), are sedentary men and women aged 50 to 75 years old, and are free of chronic cardiovascular, neurological, hepatic, renal, or metabolic disease, as determined by a health history questionnaire. As part of the screening process, participants will also be required to score 5 or higher on the CDC's prediabetes risk test (https://www.cdc.gov/prediabetes/takethetest). Finally, participants must not currently be using glucose-lowering agents or insulin.
Upon passing all inclusion and exclusion criteria, participants will confirm their address and general availability. Before any study-related procedures are completed, participants will be asked to review and sign an informed consent form. Afterward, participants will be assigned a designated requisition form for blood collection at their preferred Labcorp location. During week one of testing, after a minimum 10-hour overnight fast from food, participants will arrive at the preferred Labcorp location confirmed during enrollment and complete a venipuncture-based blood draw for the collection of fasting biomarkers. This panel will include markers used to calculate composite inflammaging burden (CIMKDM), phenotypic age, metabolic health (glucose, insulin, HbA1c, HOMA-IR, QUICKI), lipid and cardiovascular risk factors, organ function (liver, kidney), inflammatory mediators (CRP, cortisol), and complete blood count with differential. Lab results will be emailed to research staff approximately 3 to 5 business days post-collection.
On a separate day that same week, participants will complete physical and subjective testing remotely, including: (1) a grip strength assessment, conducted in triplicate on both hands using a digital hand dynamometer provided by the study team, and (2) completion of an electronic questionnaire including the Modified Fatigue Impact Scale (MFIS-21) and the Short Form-36 (SF-36) Health Survey. Instructions for standardized handgrip testing and survey completion will be provided electronically upon enrollment to the participant's email.
Following completion of baseline assessments, participants will begin daily supplementation of their prescribed study materials with their assigned treatment group: Quercefit® (500 mg/day), Ubiqsome™ (300 mg/day), or placebo, taken as one capsule in the morning and one capsule in the evening, for a total of two capsules daily over 12 weeks. Participants will be instructed to maintain consistent dosing of the supplement with water and will log compliance and adverse events routinely. Check-ins will occur at baseline, week 12, and periodically in between to monitor adherence and assess for adverse events.
On days 84 through 90 post-initial treatment, all baseline measures will be repeated following the same structure: a blood draw following an overnight fast, coordinated with the participant's preferred lab partner, followed that same week by remote grip strength testing and completion of the electronic questionnaires. Final adverse event assessments and compliance documentation will also be collected at this time. All procedures are designed to be completed remotely with direct coordination from study staff. Participants will be instructed to report any adverse events immediately and will receive regular contact throughout the study to support protocol adherence and data quality.
- Conditions
- Healthy Aging, Inflammaging, Metabolic Health, Quercetin, Coenzyme Q10
- Being tested
- Quercetin (dietary supplement), Coenzyme Q10, Rice Flour
- Keywords
- Healthy Aging, Inflammaging, Metabolic Health, Blood testing, Pre-Diabetic, Composite Inflammaging Metric, Blood Glucose Regulation, Neuromuscular Function, Fatigue Impact Scale, Quality of life
- Medical subject headings
- Glucose Intolerance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quercetin (dietary supplement)Dietary supplement
Natural compound found in foods like apples and onions that may help reduce inflammation and support overall health.
Coenzyme Q10Dietary supplement
Substance made by the body that helps produce energy in cells and also acts as an antioxidant to support heart and overall health.
Rice FlourDietary supplement
An inert carbohydrate used as the control treatment
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (Quercefit® only) | Experimental | 500 mg Quercefit® per day, administered as one 250 mg capsule taken twice daily (morning and evening) Receives: Dietary Supplement: Quercetin (dietary supplement) |
| Group 2 (Ubiqsome™ only) | Active comparator | 300 mg Ubiqsome™ per day, administered as one 150 mg capsule taken twice daily (morning and evening) Receives: Dietary Supplement: Coenzyme Q10 |
| Group 3 (Placebo) | Placebo comparator | One placebo capsule taken twice daily (morning and evening) Receives: Dietary Supplement: Rice Flour |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammaging (CIMKDM)
A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory using standardized assay protocols. Inflammaging (CIMKDM) is a biologically derived estimate of age, expressed in years, calculated from a composite of inflammatory biomarkers reflecting chronic low-grade inflammation and immune system activation. Higher values indicate a greater degree of inflammation-related biological aging.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Phenotypic Age
A fasting venous blood sample will be collected via venipuncture by a certified phlebotomist at the participant's designated Labcorp location following a minimum 10-hour overnight fast. Samples will be processed at a central laboratory. Phenotypic Age is a composite biomarker-based estimate of biological aging, expressed in years, derived from chronological age and nine clinical chemistry and hematological markers (albumin, creatinine, glucose, C-reactive protein, lymphocyte percentage, mean cell volume, red cell distribution width, alkaline phosphatase, and white blood cell count). Higher values relative to chronological age indicate accelerated biological aging.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Secondary outcomes (35)
Grip Strength
Handgrip strength will be assessed remotely using a digital hand dynamometer provided by the study team. Participants will perform three maximal isometric contractions on each hand, following standardized instructions for hand positioning and testing technique provided electronically at enrollment. The highest recorded value, in kilograms of force, will be used for analysis. This assessment serves as a practical indicator of overall muscle function and physical health.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Insulin Resistance (HOMA-IR)
Calculated from fasting glucose and fasting insulin values obtained via venipuncture blood draw at a Labcorp location following a minimum 10-hour overnight fast, using the standard HOMA-IR formula. Higher scores indicate greater insulin resistance.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Insulin Sensitivity (QUICKI)
Calculated from fasting glucose and fasting insulin values obtained via venipuncture blood draw at a Labcorp location following a minimum 10-hour overnight fast, using the standard QUICKI formula. Values typically range from approximately 0.3 to 0.4; higher values indicate better insulin sensitivity.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
High-Sensitivity C-Reactive Protein (hs-CRP)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory. hs-CRP is a marker of systemic inflammation, reported in mg/L. Higher values indicate greater inflammation.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Cortisol
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory. Cortisol serves as a marker of stress hormone status, reported in mcg/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Lipid and Cardiovascular Risk Panel
A fasting venous blood sample will be collected via venipuncture at a Labcorp location following a minimum 10-hour overnight fast and processed at a central laboratory. The panel includes total cholesterol (mg/dL), triglycerides (mg/dL), HDL cholesterol (mg/dL), LDL cholesterol (mg/dL), VLDL cholesterol (mg/dL), and the total cholesterol/HDL ratio (a calculated, unitless ratio). Together, these values are used to assess cardiovascular risk and complement biological age estimates.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Uric Acid
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Blood Urea Nitrogen (BUN)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Creatinine
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the kidney function panel. Reported in mg/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
BUN/Creatinine Ratio
Calculated from BUN and creatinine values obtained via the kidney function panel from a fasting venous blood sample. A calculated, unitless ratio used to assess kidney function.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Fatigue Impact (Modified Fatigue Impact Scale, MFIS-21)
Participants will complete the MFIS-21 electronically via a secure survey link provided at enrollment. The MFIS-21 is a 21-item self-report scale assessing the impact of fatigue on physical, cognitive, and psychosocial functioning. Each item is rated on a 5-point scale ranging from 0 ("never") to 4 ("almost always"). Item scores are summed to produce a total score ranging from 0 to 84. Higher total scores indicate greater fatigue impact (worse outcome).
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Health-Related Quality of Life (Short Form-36, SF-36)
Participants will complete the SF-36 electronically via a secure survey link provided at enrollment. The SF-36 assesses health-related quality of life across 8 domains: physical functioning, role limitations due to physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health. Question responses range from 1 to 5 or 1 to 6 depending on the item, and each domain's responses are converted to a score from 0 to 100. For all domains, higher scores indicate greater well-being.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Estimated Glomerular Filtration Rate (eGFR)
Calculated from serum creatinine, age, and sex using a standard eGFR equation applied by the central laboratory. Reported in mL/min/1.73m².
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Sodium
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Potassium
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Chloride
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mmol/L.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Calcium
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mg/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Phosphorus
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mg/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Iron
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the electrolyte/mineral panel. Reported in mcg/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Total Protein
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in g/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Albumin
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in g/dL.
Measured: Time Frame: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Bilirubin (Total)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in mg/dL.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Alanine Aminotransferase (ALT)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Aspartate Aminotransferase (AST)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Alkaline Phosphatase (ALP)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the liver function panel. Reported in U/L.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Red Blood Cell Count (RBC)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in million cells/µL.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Hemoglobin
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in g/dL.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Hematocrit
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported as a percentage.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Mean Corpuscular Volume (MCV)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in fL.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Mean Corpuscular Hemoglobin (MCH)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in pg.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Mean Corpuscular Hemoglobin Concentration (MCHC)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in g/dL.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Red Cell Distribution Width (RDW)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported as a percentage.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
White Blood Cell Count with Differential (WBC)
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in thousand cells/µL.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Platelet Count
Measured from a fasting venous blood sample collected via venipuncture at a Labcorp location and processed at a central laboratory as part of the complete blood count with differential. Reported in thousand cells/µL.
Measured: Baseline (Week 1) and Post-Intervention (Day 84 to 90)
Adverse events (AE)
Adverse events will be monitored continuously throughout the 12-week intervention via structured AE queries conducted by study staff through phone or secure digital check-in, in addition to participant self-report. All AEs will be documented and assessed for severity and relationship to the study product by the investigator.
Measured: Time Frame: Baseline (Week 1) through Post-Intervention (Day 84 to 90)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Aug 2026
- Study start18 Sep 2026 (estimated)
- Primary completionAug 2028 (estimated)
- Study completionAug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Healthy AgingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Applied Science & Performance Institute
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Jacob Wilson, PhD, Principal investigator, The Applied Science and Performance Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07760506
- Sponsor's protocol ID
- IND07125
- Status last verified
- Sep 2026
- First submitted
- 27 Jul 2026
- Last updated
- 17 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Sood B, Patel P, Keenaghan M. Coenzyme Q10. 2024 Jan 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK531491/
PubMed 30285386Riva A, Ronchi M, Petrangolini G, Bosisio S, Allegrini P. Improved Oral Absorption of Quercetin from Quercetin Phytosome(R), a New Delivery System Based on Food Grade Lecithin. Eur J Drug Metab Pharmacokinet. 2019 Apr;44(2):169-177. doi: 10.1007/s13318-018-0517-3.
PubMed 30328058Di Pierro F, Rabbani F, Tareen M, Nigar R, Khan A, Zerbinati N, Tanda ML, Cazzaniga M, Bertuccioli A, Falasca P, Damiani G, Villanova N. Potential pharmacological effect of Quercetin Phytosome in the management of hyperuricemia: results from real-life clinical studies. Front Nutr. 2025 Feb 7;12:1519459. doi: 10.3389/fnut.2025.1519459. eCollection 2025.
PubMed 39990611Han MK, Barreto TA, Martinez FJ, Comstock AT, Sajjan US. Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease. BMJ Open Respir Res. 2020 Feb;7(1):e000392. doi: 10.1136/bmjresp-2018-000392.
PubMed 32071149McKay AKA, Stellingwerff T, Smith ES, Martin DT, Mujika I, Goosey-Tolfrey VL, Sheppard J, Burke LM. Defining Training and Performance Caliber: A Participant Classification Framework. Int J Sports Physiol Perform. 2022 Feb 1;17(2):317-331. doi: 10.1123/ijspp.2021-0451. Epub 2022 Dec 29.
PubMed 34965513Liu Z, Kuo PL, Horvath S, Crimmins E, Ferrucci L, Levine M. A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study. PLoS Med. 2018 Dec 31;15(12):e1002718. doi: 10.1371/journal.pmed.1002718. eCollection 2018 Dec.
PubMed 30596641Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA, Stewart JD, Li Y, Whitsel EA, Wilson JG, Reiner AP, Aviv A, Lohman K, Liu Y, Ferrucci L, Horvath S. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018 Apr 18;10(4):573-591. doi: 10.18632/aging.101414.
PubMed 29676998